## **Product** Data Sheet



Cat. No.: HY-117684 CAS No.: 1469439-69-7 Molecular Formula:  $C_{27}H_{31}FN_{4}O_{2}$ Molecular Weight: 462.56

Target: Parasite; CaMK

Pathway: Anti-infection; Neuronal Signaling

Storage: 4°C, protect from light

\* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (216.19 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1619 mL	10.8094 mL	21.6188 mL
	5 mM	0.4324 mL	2.1619 mL	4.3238 mL
	10 mM	0.2162 mL	1.0809 mL	2.1619 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.40 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.40 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.40 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	Cabamiquine (DDD107498) is a potent and orally active antimalarial agent, inhibits multiple life-cycle stages of the parasite, with an EC <sub>50</sub> of 1 nM against P. falciparum 3D7. Cabamiquine inhibits protein synthesis by targeting eEF2/CaMKIII, with an EC <sub>50</sub> of 2 nM for WT-PfeEF2 <sup>[1]</sup> .		
IC <sub>50</sub> & Target	CaMK III	Plasmodium	
In Vitro	Cabamiquine (24-48 h) leads to abnormal trophozoites, and inhibits the development of trophozoites and schizonts in parasites, and inhibits protein synthesis <sup>[1]</sup> . Cabamiquine shows excellent activity against 3D7 parasites: EC50 =1.0 nM, EC90 = $2.4$ nM, EC99 = $5.9$ nM <sup>[1]</sup> .		

	Cabamiquine shows good metabolic stability when incubated with hepatic microsomes or hepatocyte $^{[1]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cabamiquine (p.o., a single dose) shows an ED <sub>90</sub> (90% reduction in parasitaemia) of 0.57 mg/kg in mice infected with the rodent parasite P. berghei <sup>[1]</sup> .  Cabamiquine (p.o., 3 mg/kg) shows C <sub>max</sub> of 80 ng/mL, T <sub>max</sub> of 4 h, AUC of 200542 ng·min/mL, F (%) of 84% <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Baragaña B, et al. Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. J Med Chem. 2016 Nov 10;59(21):9672-9685.

[2]. Baragaña B, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015 Jun 18;522(7556):315-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA